The Latin America, Middle East and Africa Arthritic Therapeutic Market would witness market growth of 7.4% CAGR during the forecast period (2023-2030).
The Brazil market dominated the LAMEA Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,461.1 Million by 2030. The Argentina market is showcasing a CAGR of 7.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 7% during (2023 - 2030).
Arthritic therapeutics encompass a range of interventions aimed at preserving joint integrity and promoting tissue repair in individuals with degenerative forms of arthritis, such as osteoarthritis. Joint-preserving procedures, including arthroscopy, osteotomy, and cartilage restoration techniques, help address mechanical abnormalities, redistribute load forces, and repair damaged cartilage, thereby delaying joint replacement surgery and prolonging the lifespan of affected joints.
Pain management is a central component of arthritis care, and the therapeutics encompass various modalities to reduce pain and improve functional outcomes. Physical therapy, occupational therapy, and exercise programs help strengthen muscles, improve joint flexibility, and enhance mobility, mitigating pain and improving overall physical function. Assistive devices, such as orthoses, braces, and splints, provide support and stability to arthritic joints, reducing pain and preventing further injury.
Knee osteoarthritis is becoming increasingly prevalent in the LAMEA region due to factors such as population aging, urbanization, sedentary lifestyles, and obesity. With the rising prevalence of knee osteoarthritis, there is a corresponding increase in healthcare spending in the LAMEA region as governments, healthcare systems, and payers allocate resources to address the healthcare needs of individuals with musculoskeletal conditions. Thus, due to these aspects, the market will expand across the LAMEA region in upcoming years.
Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,461.1 Million by 2030. The Argentina market is showcasing a CAGR of 7.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 7% during (2023 - 2030).
Arthritic therapeutics encompass a range of interventions aimed at preserving joint integrity and promoting tissue repair in individuals with degenerative forms of arthritis, such as osteoarthritis. Joint-preserving procedures, including arthroscopy, osteotomy, and cartilage restoration techniques, help address mechanical abnormalities, redistribute load forces, and repair damaged cartilage, thereby delaying joint replacement surgery and prolonging the lifespan of affected joints.
Pain management is a central component of arthritis care, and the therapeutics encompass various modalities to reduce pain and improve functional outcomes. Physical therapy, occupational therapy, and exercise programs help strengthen muscles, improve joint flexibility, and enhance mobility, mitigating pain and improving overall physical function. Assistive devices, such as orthoses, braces, and splints, provide support and stability to arthritic joints, reducing pain and preventing further injury.
Knee osteoarthritis is becoming increasingly prevalent in the LAMEA region due to factors such as population aging, urbanization, sedentary lifestyles, and obesity. With the rising prevalence of knee osteoarthritis, there is a corresponding increase in healthcare spending in the LAMEA region as governments, healthcare systems, and payers allocate resources to address the healthcare needs of individuals with musculoskeletal conditions. Thus, due to these aspects, the market will expand across the LAMEA region in upcoming years.
Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F.Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Market Report Segmentation
By Application- Rheumatoid Arthritis
- Psoriatic Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Others
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modified Anti-rheumatoid Drugs (DMARDs)
- Biologics
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. LAMEA Arthritic Therapeutic Market, by Application
Chapter 6. LAMEA Arthritic Therapeutic Market, by Product Type
Chapter 7. LAMEA Arthritic Therapeutic Market, by Country
Chapter 8. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Methodology
LOADING...
